Share this @internewscast.com

Expert joins CBS New York to discuss new sickle cell treatment


Expert joins CBS New York to discuss new sickle cell treatment

02:46

Britain’s medicines regulator has authorized the world’s first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K.

In a statement on Thursday, the Medicines and Healthcare Regulatory Agency said it approved Casgevy, the first medicine licensed using the gene editing tool CRISPR, which won its makers a Nobel Prize in 2020.

Casgevy — made by the Boston-based Vertex Pharmaceuticals (Europe) Ltd. and CRISPR Therapeutics — was approved by the agency for the treatment for patients with sickle cell disease and thalassemia who are 12 years old and over. 

To date, bone marrow transplants, extremely arduous procedures that come with very unpleasant side effects, have been the only long-lasting treatment.

“The future of life-changing cures resides in CRISPR based (gene-editing) technology,” said Dr. Helen O’Neill of University College London.

“The use of the word ‘cure’ in relation to sickle cell disease or thalassemia has, up until now, been incompatible,” she said in a statement, calling the MHRA’s approval of gene therapy “a positive moment in history.”

Both sickle cell disease and thalassemia are caused by mistakes in the genes that carry hemoglobin, the protein in red blood cells that carry oxygen.

In people with sickle cell — which is particularly common in people with African or Caribbean heritage — a genetic mutation causes the cells to become crescent-shaped, which can block blood flow and cause excruciating pain, organ damage, stroke and other problems.

In people with thalassemia, the genetic mutation can cause severe anemia. Patients typically require blood transfusions every few weeks, and injections and medicines for their entire life. Thalassemia predominantly affects people of South Asian, Southeast Asian and Middle Eastern heritage.

The new medicine, Casgevy, works by targeting the problematic gene in a patient’s bone marrow stem cells so that the body can make properly functioning hemoglobin.

Patients first receive a course of chemotherapy, before doctors take stem cells from the patient’s bone marrow and use genetic editing techniques in a laboratory to fix the gene. The cells are then infused back into the patient for a permanent treatment. Patients must be hospitalized at least twice — once for the collection of the stem cells and then to receive the altered cells.

Britain’s regulator said its decision to authorize the gene therapy for sickle cell disease was based on a study done on 29 patients, of whom 28 reported having no severe pain problems for at least one year after being treated. In the study for thalassemia, 39 out of 42 patients who got the therapy did not need a red blood cell transfusion for at least a year afterwards.

Gene therapy treatments can cost millions of dollars and experts have previously raised concerns that they could remain out of reach for the people who would benefit most.

Last year, Britain approved a gene therapy for a fatal genetic disorder that had a list price of £2.8 million ($3.5 million). England’s National Health Service negotiated a significant confidential discount to make it available to eligible patients.

Vertex Pharmaceuticals said it had not yet established a price for the treatment in Britain and was working with health authorities “to secure reimbursement and access for eligible patients as quickly as possible.”

In the U.S., Vertex has not released a potential price for the therapy, but a report by the nonprofit Institute for Clinical and Economic Review said prices up to around $2 million would be cost-effective. By comparison, research earlier this year showed medical expenses for current sickle cell treatments, from birth to age 65, add up to about $1.6 million for women and $1.7 million for men.

Medicines and treatments in Britain must be recommended by a government watchdog before they are made freely available to patients in the national health care system.

Casgevy is currently being reviewed by the U.S. Food and Drug Administration; the agency is expected to make a decision early next month, before considering another sickle cell gene therapy.

Millions of people around the world, including about 100,000 in the U.S., have sickle cell disease. It occurs more often among people from places where malaria is or was common, like Africa and India, and is also more common in certain ethnic groups, such as people of African, Middle Eastern and Indian descent. Scientists believe being a carrier of the sickle cell trait helps protect against severe malaria.

Dr. Jon LaPook has reported on another effort to harness gene therapy to cure sickle cell disease. Watch that story in the video below:


Could gene therapy cure sickle cell anemia?

13:35

Share this @internewscast.com
You May Also Like

Urgent Warning for Those Battling COVID or Viral Illnesses

Covid-19 is once again making its presence felt, with the new Stratus…

Effective Solutions for Balance and Dizziness Issues: Many, Including Steve, Face Challenges and GPs May Fall Short. Discover Groundbreaking Treatments that Can Transform Lives if You Know What to Request—Doctors Call Them ‘Game-Changers’

Steve Watkins used to love his life working as tennis coach, playing…

Autism Affected My Speech, But My Parents’ Unique Approach Helped Me Become a Leading News Anchor

Leland Vittert is living the dream. At 43, he has covered war…

Pharmacist Reveals Trick to ‘Cure Cold in a Day’ Using a 55p Ingredient Found in Your Kitchen

As the weather in Britain changes, colds become more common. Symptoms often…

Government Shutdown Puts Millions at Risk of Stroke and Heart Attack by Halting Essential Medical Services

Across America, individuals at risk of a health crisis now face heightened…

UK Health Secretary Wes Streeting Rebukes Trump’s Paracetamol and Autism Assertions, Advises Public to Disregard

Wes Streeting has called on Britons to heed advice from the NHS…

UK Physician Alerts NHS Patients About Health Risks Associated with Common Medication

A doctor has issued a stark warning to those who take a…

FDA Initiates Urgent Recall on Cheeses Contaminated with Potentially Fatal Bacteria

Multiple cheeses are being recalled over fears that they could cause death…

NHS Urged to Address PTSD Surge Affecting Nearly 50% of Patients Undergoing Specific Treatment

A stem cell transplant provides a second chance at life for thousands…

Research indicates that a well-known brain supplement might contribute to the development of Alzheimer’s disease.

Researchers exploring dementia have identified an amino acid that was once thought…

Long-term Use of Paracetamol May Lead to Serious Health Risks for Some Individuals

Paracetamol can be acquired without a prescription from nearly every chemist and…

Important Alert: Eggs Recalled – “Do Not Eat, Sell, or Serve”

Eggs sold in two states have been urgently recalled over fears of…